XNAS
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
IPO-related charter amendments were routine, but the quarter was ugly: EPS of **-$2.51** missed by **$3.25** with no revenue disclosure, underscoring a pre-commercial biotech profile with no visible operating leverage.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-08 | Q2 2026 | 0.74 | -2.51 | -439.19% | $0 | ❌ Miss | +0.04% | — | — |
Showing last 1 quarters.